Skip to main content
. Author manuscript; available in PMC: 2010 Jul 22.
Published in final edited form as: Eur J Clin Pharmacol. 2009 May 14;65(7):667–678. doi: 10.1007/s00228-009-0660-5

Table 5.

Median [range] of the studied short-term efficacy and safety measurements and of the change from baseline

Baselinea W2 or W4b Difference from baseline P-value
Efficacy
Log viral load (log copies/mL) 4.9 [3.4 – 6.3] 2.9 [1.8 – 4.1] −1.8 [−2.8 – −0.5] <0.001
Safety
Total cholesterol (mmol/L) 4.3 [1.9 – 7.4] 5.0 [2.9 – 7.5] 0.8 [0.8 – 4.7] <0.001
HDL cholesterol (mmol/L) 1.1 [0.5 – 1.8] 1.1 [0.4 –2.1] 0.1 [− 0.7 – 1.0] 0.09
Glycaemia (mmol/L) 4.7 [3.4 – 6.0] 4.9 [2.8 – 7.1] 0.2 [−1.0 – 2.7] 0.013
Triglycerides (mmol/L) 1.0 [0.4 – 3.0] 1.4 [0.6 – 4.0] 0.4 [−0.7 – 1.7] <0.001
Creatinine clearance (mL/min) 98.4 [62.0 – 195.7] 97.4 [62.8 – 252.0] −1.0 [−38.0 – 56.4] 0.5
a

Baseline = D0 for log viral load and W-4 for safety

b

W2 for log viral load and W4 for safety